We have an updated report [Version - 2025] available. Kindly sign up to get the sample of the report.

PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Peripheral Neuropathy Treatment Market, by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and others), by Treatment (Pharmacological Therapies(Pain Relievers, Anti-seizure Medications, Antidepressants) and Non-pharmacological Therapies (Transcutaneous Electrical Nerve Stimulation, Plasma Exchange, and Others), by End User (Hospital, Ambulatory Centers, and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In: 20 Jun, 2022
Code: CMI4363
Pages: 212
Formats: Excel and PDF
Industry: Pharmaceutical

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study:

This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global peripheral neuropathy treatment market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

Global Peripheral Neuropathy Treatment Market, By Indication :
- Diabetic Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- Others
Global Peripheral Neuropathy Treatment Market, By Treatment :
- Pharmacological Therapies
  - Pain Relievers
  - Anti-seizure Medications
  - Anti-depressants
- Non-pharmacological Therapies
  - Transcutaneous Electrical Nerve Stimulation
  - Plasma Exchange
  - Others
Global Peripheral Neuropathy Treatment Market, By End User :
- Hospital
- Ambulatory Centers
- Others
Global Peripheral Neuropathy Treatment Market, By Region:
- North America
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange

- - - - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Others
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others

- - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Abbott Laboratories*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Johnson & Johnson
- Dr. Reddy’s Laboratories Ltd
- Pfizer, Inc.
- Cipla Inc.
- Lupin Limited
- Averitas Pharma, Inc.
- NeuroBo Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

Global Peripheral Neuropathy Treatment Market, By Indication :
- Diabetic Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- Others
Global Peripheral Neuropathy Treatment Market, By Treatment :
- Pharmacological Therapies
  - Pain Relievers
  - Anti-seizure Medications
  - Anti-depressants
- Non-pharmacological Therapies
  - Transcutaneous Electrical Nerve Stimulation
  - Plasma Exchange
  - Others
Global Peripheral Neuropathy Treatment Market, By End User :
- Hospital
- Ambulatory Centers
- Others
Global Peripheral Neuropathy Treatment Market, By Region:
- North America
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange

- - - - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Others
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others

- - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Indication
    - Diabetic Peripheral Neuropathy
    - Chemotherapy-induced Peripheral Neuropathy
    - Idiopathic Peripheral Neuropathy
    - Others
  - By Application
    - Pharmacological Therapies
      - Pain Relievers
      - Anti-seizure Medications
      - Anti-depressants
    - Non-pharmacological Therapies
      - Transcutaneous Electrical Nerve Stimulation
      - Plasma Exchange
      - Others
  - By End User
    - Hospital
    - Ambulatory Centers
    - Other
  - By Country
    - South Africa
    - Central Africa
    - North Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Detailed Segmentation:

Global Peripheral Neuropathy Treatment Market, By Indication :

Global Peripheral Neuropathy Treatment Market, By Treatment :

Global Peripheral Neuropathy Treatment Market, By End User :

Global Peripheral Neuropathy Treatment Market, By Region:

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :